4.12

2.83% -0.12

Aquestive Therapeutics Inc (AQST)

Overview News Price History Option Chain Financials Discussions Forecast

Aquestive Therapeutics Inc stock is traded at $4.12, with a volume of 3.05M. It is down -2.83% in the last 24 hours and up +3.26% over the past month. Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Previous Close:

$4.24

Open:

$4.25

24h Volume:

3.05M

Relative Volume:

1.76

Market Cap:

$516.92M

Revenue:

$50.27M

Net Income/Loss:

$-68.91M

P/E Ratio:

-6.8325

EPS:

-0.603

Net Cash Flow:

$-44.32M

1W Performance:

-1.44%

1M Performance:

+3.26%

6M Performance:

+5.37%

1Y Performance:

+2.23%

1-Day Range:

$4.00

$4.255

1-Week Range:

$4.00

$4.38

52-Week Range:

$2.93

$7.55

Aquestive Therapeutics Inc Stock (AQST) Company Profile

Name

Aquestive Therapeutics Inc

Sector

Healthcare (1096)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

908-941-1900

Address

30 TECHNOLOGY DRIVE, WARREN, NJ

Employee

147

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

AQST's Discussions on Twitter

Compare AQST vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AQST Aquestive Therapeutics Inc	4.12	516.92M	50.27M	-68.91M	-44.32M	-0.603
TAK Takeda Pharmaceutical Co Adr	16.56	52.88B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.76	42.98B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	32.95	38.37B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	75.56	31.68B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	547.06	23.22B	3.17B	1.29B	1.01B	27.09

Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-24-26	Resumed	Oppenheimer	Outperform
Jun-02-25	Resumed	Oppenheimer	Outperform
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight
May-10-24	Initiated	Leerink Partners	Outperform
Apr-11-24	Initiated	Piper Sandler	Overweight
Mar-28-24	Initiated	Raymond James	Outperform
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Apr-22-19	Initiated	H.C. Wainwright	Buy
Jan-03-19	Initiated	Lake Street	Buy
Aug-20-18	Initiated	JMP Securities	Mkt Outperform
Aug-20-18	Initiated	RBC Capital Mkts	Outperform

View All

Aquestive Therapeutics Inc Stock (AQST) Latest News

Jul 10, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect - ACCESS Newswire

Jul 10, 2026

Jul 09, 2026

AQST Investors Have Opportunity to Lead Aquestive Therapeutics, I - The National Law Review

Jul 09, 2026

Jul 07, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Jul 07, 2026

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism - Investing News Network

Jul 07, 2026

Jul 05, 2026

2026-07-05 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse

Jul 05, 2026

AQSTAquestive Therapeutics Inc Short Interest - Finviz

Jul 05, 2026

Jul 04, 2026

AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review

Jul 04, 2026

Jul 02, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect - ACCESS Newswire

Jul 02, 2026

AQST News | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST) - ChartMill

Jul 02, 2026

Jun 30, 2026